BusinessSienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare ConferenceBy Nasdaq OMXDec 11, 2017, 2:05 PM UTC
BusinessSienna Biopharmaceuticals Reports Third Quarter 2017 Financial ResultsBy Nasdaq OMXNov 9, 2017, 1:05 PM UTC
BusinessSienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120By Nasdaq OMXOct 24, 2017, 1:05 PM UTC
BusinessSienna Biopharmaceuticals Reports Second Quarter 2017 Financial ResultsBy Nasdaq OMXSep 7, 2017, 12:05 PM UTC
BusinessSienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesBy Nasdaq OMXAug 1, 2017, 8:05 PM UTC
BusinessSienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common StockBy Nasdaq OMXJul 26, 2017, 11:30 PM UTC
BusinessSienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of DirectorsBy Nasdaq OMXJun 14, 2017, 1:05 PM UTC
